PropertyValue
?:abstract
  • Advanced renal cell carcinoma is not uncommon, but necessitates a multidisciplinary approach for optimal treatment. Targeted therapy has increased the likelihood of urologists managing patients in all disease stages. Neoadjuvant therapy is currently experimental. Systemic therapy for metastatic disease demonstrates survival benefits. The role of cytoreductive nephrectomy and adjuvant therapy is dependent on patient selection. Management of advanced renal cell carcinoma involves continued optimization of available agents and biomarker development. This article reviews the role of the urologist in medical and surgical therapies, including prognostication, management of locally advanced and metastatic disease, and provides the most recent clinical trial data.
is ?:annotates of
?:creator
?:doi
  • 10.1016/j.ucl.2020.04.006
?:doi
?:journal
  • The_Urologic_clinics_of_North_America
?:license
  • unk
?:pmid
?:pmid
  • 32600530.0
?:publication_isRelatedTo_Disease
?:source
  • Medline
?:title
  • Evolving Role of Urologists in the Management of Advanced Renal Cell Carcinoma.
?:type
?:year
  • 2020-08-01

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/n84leilc>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/n84leilc>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all